Trial · NCT01485796
Participant flow18
How many started, completed or left each group, period by period.
1 to 18 of 18
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Period 1: Epoch 1 (Ramp-up) | STARTED | Subcutaneous Treatment With IGI, 10% and rHuPH20 | 37 | |
| Period 1: Epoch 1 (Ramp-up) | Treated in Epoch 1 | Subcutaneous Treatment With IGI, 10% and rHuPH20 | 37 | |
| Period 1: Epoch 1 (Ramp-up) | COMPLETED | Subcutaneous Treatment With IGI, 10% and rHuPH20 | 36 | |
| Period 1: Epoch 1 (Ramp-up) | NOT COMPLETED | Subcutaneous Treatment With IGI, 10% and rHuPH20 | 1 | |
| Period 2: Epoch 2 | STARTED | Subcutaneous Treatment With IGI, 10% and rHuPH20 | 36 | |
| Period 2: Epoch 2 | Treated in Epoch 2 | Subcutaneous Treatment With IGI, 10% and rHuPH20 | 36 | |
| Period 2: Epoch 2 | COMPLETED | Subcutaneous Treatment With IGI, 10% and rHuPH20 | 1 | |
| Period 2: Epoch 2 | NOT COMPLETED | Subcutaneous Treatment With IGI, 10% and rHuPH20 | 35 | |
| Overall Trial (Incl. Safety Follow-up) | STARTED | Subcutaneous Treatment With IGI, 10% and rHuPH20 | 37 | |
| Overall Trial (Incl. Safety Follow-up) | Treated in Epoch 1 (Ramp-up) | Subcutaneous Treatment With IGI, 10% and rHuPH20 | 37 | |
| Overall Trial (Incl. Safety Follow-up) | Completed Epoch 1 (Ramp-up) | Subcutaneous Treatment With IGI, 10% and rHuPH20 | 36 | |
| Overall Trial (Incl. Safety Follow-up) | Started Epoch 2 | Subcutaneous Treatment With IGI, 10% and rHuPH20 | 36 | |
| Overall Trial (Incl. Safety Follow-up) | Treated in Epoch 2 | Subcutaneous Treatment With IGI, 10% and rHuPH20 | 36 | |
| Overall Trial (Incl. Safety Follow-up) | Completed Epoch 2 | Subcutaneous Treatment With IGI, 10% and rHuPH20 | 1 | |
| Overall Trial (Incl. Safety Follow-up) | Switch to Safety Follow-up | Subcutaneous Treatment With IGI, 10% and rHuPH20 | 26 | |
| Overall Trial (Incl. Safety Follow-up) | Completed Safety Follow-up | Subcutaneous Treatment With IGI, 10% and rHuPH20 | 24 | |
| Overall Trial (Incl. Safety Follow-up) | COMPLETED | Subcutaneous Treatment With IGI, 10% and rHuPH20 | 25 | |
| Overall Trial (Incl. Safety Follow-up) | NOT COMPLETED | Subcutaneous Treatment With IGI, 10% and rHuPH20 | 12 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01485796/flow